Cleator, Rebecca and Kirby, Michael 
ORCID: 0000-0001-9765-5641
(2023)
Exploring the clinical benefits of novel radiotherapy system HalcyonTM – a narrative review of the evidence.
[Poster]
|
PDF
RC MCK BIR 2023 poster FINAL.pdf - Other Download (335kB) | Preview |
Abstract
Abstract: Exploring the clinical benefits of novel radiotherapy system HalcyonTM – a narrative review of the evidence Introduction Approximately 50% of all cancer patients receive external beam radiotherapy (EBRT)1. A novel O-ring treatment delivery system, HalcyonTM, was released in 20172. Gantry rotation can be legally faster (for both treatment and imaging) due to being enclosed2. With a stacked/staggered higher leaf speed MLC, both on-treatment imaging and delivery can be quicker with potential improvements in plan quality, clinical outcomes, and patient experience3. This poster will focus on one of the clinical outcomes explored in this review: early-disease control. Since loco-regional failure rates correlate strongly with the incidence of overall survival, measuring early disease control may give an indication of whether improved clinical outcomes are now being realised4. Method A narrative review was conducted using the online database PubMed. Key search-terms used were as follows; ‘’Halcyon’’, ‘’O-ring linac’’ ‘’toxicit*’’, ‘’treatment time’’ and ‘’clinical’’. Inclusion and exclusion criteria were used to tighten focus onto studies identifying reported clinical results. The selected studies were analysed, appraised, and critiqued using Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and CASP methods. Results The final 11 papers included discussed clinical outcomes, including acute toxicities and early disease control, and the logistical metric, treatment delivery time. From these, 2 studies reported on early-disease control in terms of local, regional, and distant failures. The early-disease control for 16 patients with gynaecological cancers, showed local and regional failure rates of 6.25%, a distant failure rate of 12.5% and a mortality rate of 6.25%, with maximum follow-up of 7.1 months5; all comparable to published, larger trials in which patients had received EBRT on standard C-arm linacs6. Differences between trials included variability in follow-up time, cohort size and disease progression. The early-disease control for 30 lung cancer patients treated on HalcyonTM showed local, regional, and distant failure rates of 6%, 16% and 26%, respectively, with a mortality rate of 23%7. This study had a maximum follow-up time of 10.9 months; making like-for-like comparisons with published evidence (which usually reported at 12/24 months) difficult. Conclusion Our results show that early clinical outcomes using HalcyonTM are promising, however, future work should strive to define and measure clinical outcomes in a more standardised and consistent way. Further follow-up of patients treated on HalcyonTM is necessary and it is potentially still too early to quantify exactly how local control rates compare to that of standardised C-arm linac IMRT/VMAT techniques.
| Item Type: | Poster |
|---|---|
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Population Health Faculty of Health and Life Sciences > Institute of Population Health > School of Health Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 31 Mar 2023 07:29 |
| Last Modified: | 31 Mar 2023 07:29 |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3169368 |
Share
Share
